Hansen, N.L
Adult growth hormone deficiency: Diagnostic and treatment journeys from the patients perspective
First principles: when stacking makes sense vs when its just noise Heres the simplest clinical lens I know: A stack can be reasonable when it meets all 4 criteria Different primary mechanisms (true complement, not redundancy) A clear problem statement (e.g., Im losing weight but also losing lean mass vs I want to feel optimized) Human evidence exists for at least one component and the combined physiology isnt contradictory You can monitor outcomes and safety objectively (labs, body composition, symptoms, performance, vitals) A stack is usually unjustified when it has any of these patterns Redundant signaling (two compounds tugging the same rope) Unmonitorable goals (recovery, vitality, anti-aging without measurable endpoints) Axis overstimulation (especially GH/IGF-1 signaling) Quality/sterility uncertainty (common with online research vials) No exit plan (no defined stop criteria or reassessment window) The 4 major peptide lanes youll see in stacking culture Most stacks are built from some combination of these buckets: Incretin/metabolic lane (GLP-1/GIP-based pharmacologytypically FDA-approved drugs rather than peptides in the wellness sense) GH/IGF-1 lane (GHRH analogs and ghrelin receptor agonists/secretagogues) Lipolytic fragments/modulators (often marketed for fat loss
The observed sex dimorphism in inflammatory cytokines was a particularly intriguing and unexpected observation, which beyond serving as a marker of aging status, could be reflective of the relative increase and decrease in neoplasms, documented in male and female mice, respectively
Sympathetic and sensory innervation of brown adipose tissue
Are Peptides FDA-Approved
